{"id":306039,"date":"2026-10-13T16:38:58","date_gmt":"2026-10-13T11:08:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=306039"},"modified":"2026-10-13T16:38:58","modified_gmt":"2026-10-13T11:08:58","slug":"park-medi-world-shares-hospital-stock-falls-15-percent-in-a-month-will-the-stock-rebound-experts-show-road-map-supreme-court-drug-price-cap","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/park-medi-world-shares-hospital-stock-falls-15-percent-in-a-month-will-the-stock-rebound-experts-show-road-map-supreme-court-drug-price-cap\/","title":{"rendered":"Park Medi World Shares: Hospital Stock Falls 15% in a Month, Will the Stock Rebound? Experts Show Road Map to Investors on Supreme Court Drug Price Cap"},"content":{"rendered":"

Park Medi World shares: about 15% below the Rs 305 high (my calculation, from the Rs 260 support zone), after a Supreme Court hearing on 12 Oct 2026 on a drug price cap. Next hearing: 27 Oct 2026. Company says oncology is under 2% of revenue. Choice Institutional Equities target: Rs 350.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Park Medi World shares have fallen about 15% from their 52-week high of about Rs 305 to the Rs 260 support zone (my calculation), as hospital stocks reacted to a Supreme Court hearing on 12 October 2026 about capping drug prices and retailer margins. The company says oncology and chemotherapy are under 2% of its revenue, so it expects a negligible financial impact, and its average revenue per occupied bed is Rs 30,444. The next hearing is on 27 October 2026, and Choice Institutional Equities kept a Buy with a Rs 350 target in July. Watch the Rs 260 support and the Rs 305.25 high, and read the court outcome before you add.<\/p>\n<\/p><\/div>\n

Park Medi World shares came under pressure after the Supreme Court asked the government why drug prices and margins at hospitals should not be capped. The stock is the second-largest private hospital chain in North India, and it fell as much as 6% on 12 October along with Apollo, Max Healthcare, Fortis and Aster DM.<\/p>\n

This guide covers the court hearing, how much of the business a drug price cap could touch, the price levels analysts and data pages are watching, the expansion plan behind the Rs 350 target and the risks. Sources differ on some price data, so I flag every conflict.<\/p>\n

Anyone holding Park Medi World shares should separate the short term court headline from the long term bed expansion story.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n